Home » Treatment » Vimovo MR tablets (naproxen/esomeprazole)
Vimovo MR tablets (naproxen/esomeprazole)
from£29.99
Vimovo MR tablets are a modified-release prescription medicine combining naproxen 500mg and esomeprazole 20mg in a bilayer tablet for the symptomatic relief of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis in adults at risk of NSAID-associated gastrointestinal ulcers.
Manufactured by Grünenthal Ltd, the modified-release formulation delivers esomeprazole immediately and naproxen in a delayed, enteric-coated release for simultaneous NSAID therapy and gastroprotection.
Vimovo MR tablets (naproxen/esomeprazole) are modified-release, bilayer prescription tablets that combine naproxen 500mg and esomeprazole (as magnesium) 20mg in one dose. Naproxen is a well-known non-steroidal anti-inflammatory drug (NSAID) that helps reduce pain and inflammation. Vimovo supports long-term treatment for chronic musculoskeletal and inflammatory joint conditions, such as osteoarthritis and rheumatoid arthritis.
How does Vimovo work?
Vimovo pairs an anti-inflammatory medicine with built-in stomach protection. Naproxen eases pain and swelling. Esomeprazole is a proton pump inhibitor (PPI), which means it reduces stomach acid. As a result, it helps protect the stomach lining from irritation and ulcers that NSAIDs can cause.
Grünenthal Ltd designed Vimovo to make NSAID treatment simpler. Instead of taking naproxen and a separate PPI, you take one tablet. So you take fewer tablets, and you’re more likely to take the stomach protection consistently.
The modified-release tablet (why the design matters)
Vimovo’s tablet design isn’t just clever—it’s the whole point.
Outer layer (immediate release): contains esomeprazole. It dissolves first and starts lowering stomach acid straight away.
Inner layer (delayed release): contains naproxen. An enteric coating helps it pass through the stomach intact, then dissolve in the small intestine.
Because of this sequence, esomeprazole gets a head start. Meanwhile, the naproxen avoids dissolving directly in the stomach, which can reduce irritation.
Clinical studies also show lower rates of gastric and duodenal ulcers with Vimovo compared with naproxen alone. So, for the right patient, it can offer a safer way to use naproxen long term.
Vimovo is a prescription-only medicine (POM)
Vimovo MR tablets are prescription-only in the UK. That’s because NSAIDs need careful use, especially with long-term treatment. Your prescriber should check key risks first, including:
stomach and gut ulcer risk
kidney function
cardiovascular risk (heart and circulation)
other medicines (to avoid interactions)
Courier Pharmacy offers a secure online consultation with a UK-registered prescriber, so you can check suitability and access treatment without the hassle of a traditional appointment.
Suitable for: adults who need NSAID treatment for osteoarthritis, rheumatoid arthritis, or ankylosing spondylitis, especially if they have a higher risk of NSAID-related stomach ulcers
Usual dose: 1 tablet twice daily, taken at least 30 minutes before food
Additional information
Quantity
1 x 60, 2 x 60, 3 x 60
MOJO WISDOM
Take control of your health by understanding your condition and what this medication is doing for you.
READ:
More information about this treatment.
UK-based doctors and pharmacists
Discreet and Confidential
UK-based doctors and pharmacists
Free, Expert Advice
No video link provided.
No video link provided.
UK-based doctors and pharmacists
Free, expert advice
Discrete and confidential
Fast delivery
Giving you trusted clinical advice for over 40 conditions
A UK regulated pharmacy providing safe, effective treatments online since 2014
Naproxen that comes with its own stomach protection built in — that is the idea behind Vimovo MR tablets
If you have been prescribed naproxen before and found it hard on your stomach, or if your prescriber has suggested you take a proton pump inhibitor alongside your NSAID, Vimovo MR tablets may be exactly the kind of intelligent combination you have been waiting for.
Each modified-release tablet contains naproxen 500mg for anti-inflammatory pain relief and esomeprazole 20mg to protect the stomach lining from the gastric effects that NSAIDs are known to cause. The two ingredients are combined in a single bilayer tablet, so you get the pain relief and the gastroprotection together, without having to remember a separate stomach tablet.
Manufactured by Grünenthal Ltd and available only on prescription, Vimovo MR tablets are designed for adults who need an NSAID for chronic inflammatory conditions and who are at risk of NSAID-associated gastric complications. At Courier Pharmacy, we believe healthcare should fit the person. For people managing conditions like arthritis or chronic musculoskeletal pain alongside general chronic illness, that kind of personalised, protective prescribing matters a great deal.
Five things worth knowing straight away
Vimovo MR tablets combine naproxen 500mg and esomeprazole 20mg in a single modified-release bilayer tablet, delivering both an NSAID and gastroprotection in one dose.
They are a prescription-only medicine (POM); you will need a valid UK prescription from a registered prescriber to obtain them.
The esomeprazole component is a proton pump inhibitor (PPI) that reduces stomach acid production, significantly lowering the risk of NSAID-associated gastric ulcers and upper gastrointestinal complications.
The modified-release formulation delays naproxen release until the tablet has passed through the stomach, while allowing esomeprazole to be released immediately to begin gastroprotection before the NSAID reaches the duodenum.
Vimovo MR tablets are indicated for symptomatic relief of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis in adults who are at risk of NSAID-associated gastrointestinal ulcers.
Treatment dosage: Vimovo MR tablets
Always take Vimovo MR tablets exactly as directed by your prescriber. The information below is based on the Summary of Product Characteristics (SmPC) and BNF guidance and should not replace personalised medical advice.
The standard adult dose is one tablet taken twice daily, once in the morning and once in the evening. Each dose should be taken at least 30 minutes before a meal. This pre-meal timing is essential to the formulation’s function: esomeprazole requires an acid environment in the stomach to be fully activated via its prodrug mechanism, and taking it before food, when the parietal cells are about to be stimulated by eating, maximises its acid-suppressing effect. Taking Vimovo after food may reduce the efficacy of the esomeprazole component.
Vimovo MR tablets must be swallowed whole. Do not crush, break, chew, or dissolve the tablets. The modified-release coating is central to the formulation’s gastroprotective mechanism; breaking the tablet destroys this and exposes the naproxen directly to the stomach lining. If you find it difficult to swallow the tablet whole, speak to your prescriber about whether an alternative formulation is more appropriate for you.
The lowest effective dose for the shortest duration consistent with treatment goals is the recommended approach for all NSAIDs. Your prescriber will determine the appropriate duration of Vimovo therapy and will review the need for continued treatment at regular intervals. Long-term NSAID use carries cumulative cardiovascular and renal risks that require periodic clinical reassessment even when gastrointestinal protection is provided by the esomeprazole component.
Overview of Vimovo MR tablets
Five key facts
The bilayer design of Vimovo MR tablets is not simply a co-formulation convenience; it is a pharmacokinetically designed sequential delivery system where esomeprazole precedes naproxen release by design, producing measurable gastroprotection before NSAID exposure.
Clinical trials of Vimovo showed a reduction in the incidence of endoscopically confirmed gastric ulcers by approximately 70 percent compared with enteric-coated naproxen alone in patients at risk of NSAID-associated gastrointestinal complications.
Esomeprazole is the S-enantiomer of omeprazole and is one of the most potent and predictable PPIs available; at 20mg twice daily, it achieves sustained intragastric pH elevation that is protective against both NSAID-induced direct mucosal injury and acid-pepsin-mediated ulceration.
The 30-minute pre-meal timing requirement is a clinically meaningful instruction, not an administrative note; PPI efficacy is substantially reduced when taken at the wrong time relative to meals.
Vimovo is specifically indicated for patients at risk of NSAID-associated GI ulcers; it is not intended as a general naproxen substitute for people without this risk, as it subjects patients who do not need gastroprotection to esomeprazole unnecessarily.
The clinical problem Vimovo was designed to solve is a real and well-documented one. NSAIDs are among the most commonly prescribed medicines in the world and among the most effective for chronic inflammatory conditions. They are also among the most common causes of serious gastrointestinal complications, including upper gastrointestinal bleeding and perforation, which carry significant morbidity and mortality. The risk is not uniform: it is substantially higher in older adults, people with a previous history of peptic ulcer disease, those taking corticosteroids or anticoagulants, and those with Helicobacter pylori infection. For people in these higher-risk groups who nevertheless need NSAID therapy for a chronic inflammatory condition, the standard of care has long been to co-prescribe a PPI alongside the NSAID.
The problem with co-prescribing, as opposed to a fixed combination, is adherence. Studies consistently show that patients prescribed multiple medicines take them less reliably than patients prescribed fewer. When a PPI and an NSAID are prescribed separately, the PPI is more likely to be omitted, particularly as symptoms improve and the perceived need for the stomach tablet diminishes. A fixed-combination product like Vimovo sidesteps this by making the gastroprotection inseparable from the analgesic dose; you cannot take the naproxen without simultaneously receiving the esomeprazole.
Naproxen’s pharmacological profile makes it a well-chosen NSAID for this combination. Among commonly used NSAIDs, naproxen has a relatively favourable cardiovascular risk profile, with some evidence suggesting it is associated with a lower rate of serious cardiovascular events than other non-selective NSAIDs such as diclofenac or high-dose ibuprofen. This is relevant because patients requiring chronic NSAID therapy for inflammatory conditions often have comorbidities including hypertension, dyslipidaemia, and established cardiovascular disease. The cardiovascular profile of naproxen does not eliminate cardiovascular risk from NSAID use, but it is a meaningful consideration in prescriber decision-making.
For people managing chronic inflammatory conditions such as rheumatoid arthritis alongside other complex health challenges, including general chronic illness or CFS/ME, the integration of gastroprotection into the NSAID prescription is also an example of the kind of thoughtful, whole-person prescribing that makes a real difference to daily quality of life. Fewer tablets, less to remember, and built-in protection without having to advocate for a separate PPI prescription. At Courier Pharmacy, that kind of joined-up care is something we support actively.
The 60-tablet pack provides exactly one month of treatment at the standard twice-daily dose, which is practical for monthly prescription review cycles and aligns with the monitoring requirements for long-term NSAID therapy. Prescribers reviewing Vimovo therapy at monthly intervals will typically assess symptom control, renal function if clinically indicated, blood pressure, and the continued need for NSAID therapy at the current dose.
Why choose Courier Pharmacy for Vimovo MR tablets
At Courier Pharmacy, our service exists because healthcare should fit the person, not force the person to navigate a system that was not built with them in mind. For Vimovo MR tablets, that means a prescribing consultation that actually engages with your full picture: your inflammatory condition, your gastrointestinal history, your cardiovascular risk, and everything else your prescriber needs to know to confirm that this is the right treatment for you. Our approach is shaped by Dr Ada Jex-Cori, our brand pharmacist, who has built a practice around accessible, honest, evidence-led care. Her philosophy is one we share: you are not broken. The system is. We are here to change that.
For people managing chronic inflammatory conditions like rheumatoid arthritis or ankylosing spondylitis alongside other complex health challenges, Vimovo’s integrated gastroprotection is often exactly the kind of practical, person-centred prescribing that makes a meaningful difference. If you have previously been prescribed naproxen and a separate PPI and found the two-tablet regimen difficult to maintain, or if your prescriber has suggested that a fixed combination might improve your adherence and your gastric safety, our online consultation service is designed to make that process straightforward.
Trust is not claimed; it is earned through transparency, regulation, and consistency. Courier Pharmacy operates under GPhC oversight, sources clinical content from NHS, NICE, BNF, and peer-reviewed references, and will tell you clearly if Vimovo is not appropriate for your situation. If it is not suitable, our prescriber will explain why and identify what is.
Buy Vimovo MR tablets (prescription only) from Courier Pharmacy
Vimovo MR tablets are a prescription-only medicine (POM). You cannot purchase them without a valid UK prescription issued by a registered prescriber. At Courier Pharmacy, we offer a secure online consultation with a UK-registered prescriber to make this process accessible without the need for an in-person GP appointment.
Here is how it works:
Complete a quick online consultation answering questions about your condition, medical history, cardiovascular and gastrointestinal risk factors, and current medications.
A UK-registered prescriber reviews your answers, usually within one working day.
If Vimovo MR tablets are clinically appropriate for you, a prescription is issued electronically.
We dispense and deliver discreetly to your door.
If Vimovo MR tablets are not suitable for you, we will explain why and suggest the next best option. We would rather give you the right treatment than a quick transaction.
If you are in or near Derby, our free fortnightly drop-in clinics at Insomnia run every other fortnight from 10 am to 12 pm. Managing long-term inflammatory conditions, understanding NSAID safety, and knowing what to ask your prescriber are topics that come up regularly. No appointment, no charge, no pressure.
Active ingredients in Vimovo MR tablets
Each Vimovo MR tablet contains two active ingredients delivered via a bilayer modified-release system. Naproxen 500mg is a propionic acid derivative NSAID that inhibits both cyclo-oxygenase-1 (COX-1) and COX-2 enzymes, reducing the synthesis of prostaglandins, prostacyclins, and thromboxanes at sites of inflammation. Its plasma half-life of approximately 12 to 17 hours allows twice-daily dosing rather than the three or four times daily dosing required for shorter-acting NSAIDs, which is an important practical advantage for people managing a chronic condition. The naproxen in Vimovo is formulated as a delayed-release (enteric-coated) inner layer, bypassing the stomach and dissolving in the less acidic environment of the small intestine.
Esomeprazole magnesium 20mg is the S-enantiomer of omeprazole and a second-generation proton pump inhibitor. It irreversibly inhibits the hydrogen-potassium ATPase enzyme (the proton pump) in the parietal cells of the stomach lining, blocking the final step of gastric acid secretion. At 20mg taken before meals twice daily, esomeprazole achieves substantial elevation of intragastric pH, reducing the acidic environment that potentiates direct NSAID-induced mucosal injury and ulceration. The esomeprazole in Vimovo is formulated as the immediate-release outer layer of the bilayer tablet, dissolving in the stomach to begin acid suppression before the naproxen is released further along the gastrointestinal tract.
What are Vimovo MR tablets used for?
Vimovo MR tablets are indicated for the symptomatic relief of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis in adults who are at risk of developing NSAID-associated gastric and duodenal ulcers and who require treatment with naproxen 500mg twice daily. The key qualification is the at-risk designation: Vimovo is not a standard naproxen substitute for all patients, but specifically for those in whom the clinical benefit of built-in gastroprotection justifies the fixed-dose combination.
Patients at risk of NSAID-associated ulcers include those aged 65 and over, those with a personal history of peptic ulcer disease or gastrointestinal bleeding, those taking corticosteroids concurrently, those on anticoagulant or antiplatelet therapy, and those who smoke or consume alcohol regularly. The decision to use Vimovo over a standard naproxen plus separate PPI regimen is primarily one of adherence: for patients who are likely to take their gastroprotection consistently alongside their NSAID, the clinical outcome difference between the fixed combination and co-prescribing may be modest. For patients where adherence to a multi-tablet regimen is a practical challenge, the fixed combination provides a meaningful clinical advantage.
Vimovo is not appropriate as a treatment for acute or short-term pain, as the gastroprotective benefit accumulates over time and the NSAID dose is fixed at 500mg twice daily. For people who need naproxen at a lower dose, or who need it intermittently rather than continuously, a standard naproxen formulation with a separately prescribed PPI when clinically indicated is more appropriate. Your prescriber will determine whether Vimovo's fixed-dose approach is the right fit for your specific clinical situation.
How does Vimovo MR tablets work?
The naproxen component works by inhibiting cyclo-oxygenase enzymes, specifically COX-1 and COX-2, which are responsible for converting arachidonic acid into prostaglandins. Prostaglandins are signalling molecules that drive the inflammatory cascade, sensitise pain receptors, cause vasodilation and oedema, and contribute to the joint destruction seen in rheumatoid arthritis and other inflammatory conditions. By reducing prostaglandin synthesis at sites of inflammation, naproxen decreases pain, swelling, stiffness, and the systemic features of inflammatory joint disease. Its relatively long half-life means that twice-daily dosing maintains reasonably consistent plasma concentrations throughout the day and overnight, which is particularly relevant for morning stiffness in rheumatoid arthritis and ankylosing spondylitis.
The COX-1 inhibition by naproxen is the pharmacological source of its gastrointestinal risk. COX-1 is constitutively expressed in the gastric mucosa, where its prostaglandin products maintain the protective mucus layer, stimulate bicarbonate secretion, and promote mucosal blood flow. When COX-1 is inhibited by an NSAID, this protective prostaglandin activity is reduced, leaving the stomach lining more vulnerable to injury from gastric acid and pepsin. This is the mechanism underlying NSAID-associated gastric and duodenal ulcers, and it is the problem that the esomeprazole component of Vimovo is designed to address.
Esomeprazole works by irreversibly inhibiting the proton pump, the hydrogen-potassium ATPase enzyme located on the luminal surface of parietal cell secretory membranes in the stomach. The proton pump is the final common pathway for gastric acid secretion; by blocking it irreversibly, esomeprazole reduces acid output from all stimuli (histamine, gastrin, and acetylcholine) rather than blocking just one signalling pathway. This produces a sustained and profound reduction in intragastric acidity, typically raising intragastric pH from around 1 to 2 at baseline to 4 to 5 or above during treatment. At this higher pH, the direct injury to gastric mucosa from acid and pepsin is substantially reduced.
The sequential delivery mechanism of the Vimovo bilayer is where the pharmacokinetic elegance lies. Because esomeprazole is released first from the outer layer in the stomach, it begins suppressing acid production approximately 30 to 60 minutes before the enteric-coated naproxen layer begins dissolving in the small intestine. By the time naproxen enters systemic circulation and begins exerting its COX-1 inhibitory effect on the gastric mucosa, the proton pump is already partially inhibited and gastric acid output is already reduced. This sequential action is more mechanistically protective than taking naproxen and a PPI simultaneously, and substantially more protective than taking naproxen without a PPI at all.
Naproxen's systemic anti-inflammatory effect is not diminished by the delayed-release formulation; the naproxen is absorbed from the small intestine and reaches plasma concentrations and the target joints via the bloodstream in the same way as standard naproxen. The delayed release affects only the route of absorption, not the extent. Bioavailability studies of Vimovo confirm that naproxen from the modified-release formulation is bioequivalent to standard naproxen preparations at comparable doses.
How to use Vimovo MR tablets
Take one Vimovo MR tablet at least 30 minutes before your morning meal and one tablet at least 30 minutes before your evening meal. The pre-meal timing is not optional; it is essential to esomeprazole's mechanism of action. PPIs are prodrugs that are activated in the acidic environment of the secretory canaliculi of parietal cells. Parietal cells are most active and have the most proton pumps available for inhibition when they are stimulated by the anticipation of food. Taking the tablet before the meal, when acid secretion is about to be triggered, maximises the proportion of proton pumps that the esomeprazole can reach and inhibit. Taking it after food, when acid secretion is already subsiding, significantly reduces its effectiveness.
Swallow the tablet whole with a full glass of water. Do not crush, break, split, or chew the tablet under any circumstances. The modified-release coating is the mechanism by which the naproxen bypasses the stomach; disrupting the coating exposes the naproxen to the gastric mucosa in exactly the way the formulation was designed to prevent. If swallowing large tablets is genuinely difficult, speak to your prescriber about alternatives rather than attempting to divide the tablet.
Keep a consistent schedule. Naproxen's analgesic and anti-inflammatory effect in chronic inflammatory conditions builds over time with regular dosing; it is not simply an on-demand painkiller. Regular twice-daily dosing maintains a steady naproxen plasma concentration, which provides more consistent anti-inflammatory coverage than irregular use. If you miss a dose, take it as soon as you remember, provided it is at least 30 minutes before food and at least four hours before the next scheduled dose. Do not double up to compensate for a missed dose. Contact your prescriber if you are uncertain how to manage a missed dose within your specific treatment schedule.
Warnings and precautions for Vimovo MR tablets
Vimovo MR tablets are contraindicated in people with known hypersensitivity to naproxen, esomeprazole, any other NSAID, any benzimidazole, or any excipient of the product. NSAID hypersensitivity includes NSAID-exacerbated respiratory disease (aspirin-sensitive asthma), where naproxen can trigger bronchospasm. It is also contraindicated in active peptic ulceration or gastrointestinal bleeding, severe hepatic impairment, severe renal impairment, severe heart failure, in the third trimester of pregnancy, and in people taking atazanavir or nelfinavir (HIV medicines that require gastric acid for absorption).
Cardiovascular risk must be assessed before and during Vimovo therapy. All NSAIDs, including naproxen, are associated with a small but dose and duration-dependent increase in the risk of serious cardiovascular events including myocardial infarction and stroke. This risk is greatest in people with established cardiovascular disease or significant cardiovascular risk factors. The relatively favourable cardiovascular profile of naproxen compared with some other NSAIDs does not eliminate this risk. Blood pressure should be monitored in people with hypertension during NSAID therapy, and fluid retention may worsen heart failure.
Renal function should be monitored with long-term Vimovo use. NSAIDs reduce renal prostaglandin synthesis, which can impair renal blood flow and lead to fluid retention, oedema, or in susceptible individuals, acute kidney injury. The risk is higher in older adults, those who are dehydrated, and those with pre-existing renal disease. Diuretics and ACE inhibitors also increase this risk when used concurrently. If renal function deteriorates during Vimovo therapy, dose reduction or discontinuation should be discussed with your prescriber.
Long-term PPI use, including the esomeprazole component of Vimovo, carries its own considerations. Prolonged acid suppression is associated with a small increase in the risk of Clostridium difficile infection, community-acquired pneumonia, hypomagnesaemia, vitamin B12 deficiency, and osteoporosis-related fractures. These risks are generally low at standard doses over typical treatment durations, but they are worth discussing with your prescriber in the context of long-term Vimovo therapy.
Pregnancy and breastfeeding: NSAIDs are contraindicated in the third trimester and should be avoided in the first and second trimesters unless clearly necessary. Esomeprazole should be used during pregnancy only when clinically indicated and under medical supervision. Both naproxen and esomeprazole pass into breast milk; breastfeeding is not recommended during Vimovo treatment. If you are pregnant, planning a pregnancy, or breastfeeding, discuss your pain management options with your prescriber before starting or continuing Vimovo.
Side effects of Vimovo MR tablets
The most commonly reported side effects of Vimovo MR tablets span both the naproxen and esomeprazole components. Gastrointestinal effects, somewhat paradoxically given the gastroprotective formulation design, remain the most frequently reported category: nausea, diarrhoea, abdominal pain, and dyspepsia can occur. The esomeprazole component substantially reduces the risk of serious upper GI events compared with naproxen alone, but mild gastrointestinal symptoms can still occur. Headache and dizziness are also among the commonly reported effects, as are peripheral oedema (ankle swelling) from the NSAID's effect on renal prostaglandins.
Less common side effects include constipation, flatulence, dry mouth, and elevated liver enzymes. Skin reactions including rash, pruritus, and photosensitivity can occur with both naproxen and esomeprazole. Tinnitus is a recognised effect of naproxen at higher doses or in sensitive individuals; if you notice ringing in the ears during treatment, report it to your prescriber. Hypomagnesaemia (low blood magnesium) can occur with prolonged PPI use and may present as muscle cramps, fatigue, or irregular heartbeat.
Rare but serious side effects include severe gastrointestinal events including ulceration, perforation, and bleeding despite esomeprazole co-administration (the combination reduces but does not eliminate this risk), severe hypersensitivity reactions including anaphylaxis, Stevens-Johnson syndrome, renal impairment including acute kidney injury, hepatotoxicity, and cardiovascular events. Clostridium difficile-associated diarrhoea, presenting as watery or bloody diarrhoea during or after antibiotic treatment in the context of PPI use, requires urgent medical assessment.
Report suspected adverse drug reactions to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. Both patient and healthcare professional reports contribute to ongoing post-market surveillance.
Drug interactions with Vimovo MR tablets
The interaction profile of Vimovo MR tablets encompasses both naproxen and esomeprazole. Tell your prescriber and pharmacist about all medicines, supplements, and herbal remedies you are taking before starting Vimovo.
Other NSAIDs, including aspirin, ibuprofen, and diclofenac, should not be taken concurrently with Vimovo. Combining NSAIDs increases gastrointestinal, cardiovascular, and renal risks additively without providing additional anti-inflammatory benefit. Low-dose aspirin taken for cardiovascular prophylaxis can be continued alongside Vimovo but increases upper GI risk; the esomeprazole component provides some mitigation, but the prescriber should be aware of all concurrent aspirin use.
Anticoagulants and antiplatelets interact with the naproxen component through its antiplatelet effect and through NSAID-mediated inhibition of the gastric mucosal barrier. Warfarin, DOACs, clopidogrel, and similar agents all increase bleeding risk when combined with NSAIDs. If you are on anticoagulation therapy, your prescriber will weigh this risk carefully and may choose additional gastroprotective measures or an alternative analgesic.
The esomeprazole component interacts with medicines whose absorption depends on gastric acidity. Atazanavir and nelfinavir (HIV antiretrovirals) are contraindicated with Vimovo because they require a low gastric pH for absorption; esomeprazole's acid suppression renders them ineffective. Clopidogrel is metabolised via CYP2C19 to its active form; esomeprazole, also a CYP2C19 inhibitor, reduces clopidogrel activation and may reduce its antiplatelet efficacy. Methotrexate excretion may be reduced by PPIs through inhibition of renal tubular transporters, increasing methotrexate toxicity risk. Digoxin, ketoconazole, itraconazole, and erlotinib levels may be affected by the pH-dependent changes in gastrointestinal absorption.
Lithium and methotrexate plasma levels may be increased by naproxen through reduced renal clearance. Diuretics, ACE inhibitors, and ARBs may have their antihypertensive and natriuretic effects reduced by naproxen's renal prostaglandin inhibition. Corticosteroids combined with NSAIDs significantly increase gastrointestinal risk. SSRIs and SNRIs add to the risk of gastrointestinal bleeding when combined with NSAIDs, through reduction of serotonin-mediated platelet aggregation. Ciclosporin and tacrolimus nephrotoxicity may be increased by concurrent NSAID use.
Frequently asked questions about Vimovo MR tablets
What are Vimovo MR tablets used for?
Vimovo MR tablets are indicated for the symptomatic relief of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis in adults who require treatment with naproxen 500mg twice daily and who are at risk of developing NSAID-associated gastric or duodenal ulcers. They are a prescription-only medicine and require a valid UK prescription from a registered prescriber.
What is the difference between Vimovo and standard naproxen?
Standard naproxen tablets deliver naproxen without built-in gastroprotection. Vimovo MR tablets contain naproxen 500mg combined with esomeprazole 20mg in a bilayer modified-release formulation: the esomeprazole is released immediately in the stomach to suppress acid, while the naproxen is released in the small intestine after the stomach has been partially protected. Clinical studies showed significantly lower gastric ulcer rates with Vimovo compared with naproxen alone.
Why must Vimovo MR tablets be taken before food?
Esomeprazole, the PPI component, must be taken before a meal to work effectively. PPIs are activated in the parietal cells when those cells are actively secreting acid in anticipation of food. Taking esomeprazole before eating maximises the proportion of active proton pumps available for irreversible inhibition. Taking it after food, when acid secretion is subsiding, significantly reduces its efficacy. The 30-minute pre-meal instruction is therefore a clinical requirement, not simply a preference.
Can Vimovo MR tablets be broken or crushed?
No. Vimovo MR tablets must be swallowed whole. The modified-release coating on the naproxen inner layer is designed to prevent naproxen from dissolving in the stomach; breaking or crushing the tablet destroys this coating and allows naproxen to come into direct contact with the gastric mucosa, negating the gastroprotective purpose of the formulation and potentially causing gastric injury.
Who is Vimovo MR tablets suitable for?
Vimovo is suitable for adults who need naproxen 500mg twice daily for osteoarthritis, rheumatoid arthritis, or ankylosing spondylitis and who are at heightened risk of NSAID-associated gastrointestinal ulcers. Risk factors include age over 65, a previous history of peptic ulcer or GI bleeding, concurrent use of corticosteroids or anticoagulants, regular alcohol consumption, and smoking. A prescriber will assess your individual risk profile before recommending Vimovo.
Can I take other pain medicines alongside Vimovo MR tablets?
Do not take other NSAIDs, including ibuprofen or aspirin at analgesic doses, alongside Vimovo. Adding another NSAID increases gastrointestinal, cardiovascular, and renal risks without additional benefit. Paracetamol can generally be used alongside Vimovo if additional analgesia is needed, but confirm with your prescriber or pharmacist as part of your overall pain management plan.
Does Vimovo MR tablets completely prevent stomach ulcers?
No. Vimovo significantly reduces but does not eliminate the risk of NSAID-associated gastric and duodenal ulcers. Clinical trials showed approximately 70 percent reduction in endoscopically confirmed gastric ulcers compared with naproxen alone in at-risk patients. A small residual risk of serious gastrointestinal events remains, which is why symptoms such as new abdominal pain, blood in stools, or vomiting blood during treatment should prompt immediate medical attention.
Can I drink alcohol while taking Vimovo MR tablets?
Alcohol should be avoided or minimised during Vimovo treatment. Alcohol increases the risk of gastrointestinal mucosal injury and bleeding when combined with an NSAID, and it contributes to the gastrointestinal risk that the esomeprazole component is designed to mitigate. Combining alcohol with naproxen reduces the gastroprotective benefit of the esomeprazole component and increases overall upper GI risk.
How long does it take for Vimovo MR tablets to work?
The anti-inflammatory and analgesic effect of naproxen in chronic conditions builds over days to weeks of regular dosing. Some improvement in pain and stiffness may be noticeable within the first few days, but the full anti-inflammatory benefit of regular twice-daily naproxen typically develops over one to two weeks. Esomeprazole's acid suppression begins within the first one to two days and reaches its maximum effect within three to five days of regular use.
What should I do if I miss a dose of Vimovo MR tablets?
Take the missed dose as soon as you remember, provided it is at least 30 minutes before a meal and at least four hours before your next scheduled dose. If it is closer to the time for your next dose, skip the missed dose and continue with your regular schedule. Do not take two doses at once to compensate. Contact your prescriber or pharmacist if you are unsure how to manage a missed dose in the context of your treatment schedule.
Can Vimovo MR tablets affect the kidneys?
Yes. The naproxen component can reduce renal prostaglandin synthesis and thereby impair renal blood flow, potentially causing fluid retention, oedema, or in susceptible individuals, acute kidney injury. This risk is higher in older adults, those who are dehydrated, those with pre-existing renal disease, and those taking diuretics or ACE inhibitors. Renal function monitoring may be recommended by your prescriber during long-term Vimovo therapy.
Does long-term use of Vimovo MR tablets cause any concerns beyond the stomach?
Long-term use of both the naproxen and esomeprazole components carries considerations beyond gastrointestinal safety. For naproxen, these include cardiovascular risk and renal effects. For esomeprazole, long-term PPI use is associated with a small increase in risk of hypomagnesaemia, vitamin B12 deficiency, Clostridium difficile infection, osteoporosis-related fractures, and community-acquired pneumonia. Your prescriber will review the ongoing risk-benefit of Vimovo therapy at regular intervals.
Is Vimovo suitable during pregnancy?
No. Naproxen is contraindicated in the third trimester of pregnancy due to risks including premature closure of the ductus arteriosus and inhibition of labour. It should be avoided in the first and second trimesters unless clearly necessary under medical supervision. Esomeprazole should only be used in pregnancy when clinically indicated. If you are pregnant or planning a pregnancy, discuss all pain management options with your prescriber or midwife before continuing Vimovo.
Can I take Vimovo MR tablets with my heart or blood pressure medicines?
This requires careful prescriber assessment. NSAIDs can reduce the effectiveness of antihypertensives including ACE inhibitors, ARBs, beta-blockers, and diuretics, and can cause fluid retention that worsens blood pressure control. The esomeprazole component interacts with clopidogrel by reducing its activation via CYP2C19 inhibition. If you are taking any cardiovascular medicines, ensure your prescriber knows your full medication list before starting Vimovo.
What is the difference between Vimovo and taking naproxen with a separate omeprazole?
Clinically, both approaches aim to deliver NSAID therapy with PPI gastroprotection. The principal difference is adherence: with separate tablets, patients may take the NSAID without the PPI, losing the gastroprotective benefit. Vimovo's fixed combination makes omission impossible. There is also a pharmacokinetic advantage in the bilayer design: esomeprazole's immediate release precedes naproxen's delayed release, providing sequential gastroprotection. Omeprazole and esomeprazole are closely related PPIs with comparable efficacy.
Can Vimovo MR tablets be used for acute pain?
Vimovo is not designed or licensed for acute or short-term pain management. The fixed naproxen dose of 500mg twice daily and the gastroprotective mechanism that builds over days make it appropriate only for the ongoing management of chronic inflammatory conditions. For acute or short-term pain, a standard naproxen or other NSAID formulation, used for the minimum necessary duration, is more appropriate.
Why does Vimovo contain esomeprazole rather than omeprazole?
Esomeprazole is the S-enantiomer of omeprazole and has a marginally more predictable pharmacokinetic profile with somewhat higher bioavailability and more consistent acid suppression across patient populations. Grünenthal chose esomeprazole for the Vimovo formulation on the basis of this consistent efficacy profile. In clinical practice, the difference between esomeprazole and omeprazole at comparable doses is modest, but the choice was pharmacologically deliberate.
Can Vimovo MR tablets interact with my reflux or heartburn medicines?
If you are already taking a PPI (such as omeprazole, lansoprazole, or pantoprazole) for acid reflux, taking Vimovo simultaneously adds a second PPI dose. Your prescriber should review whether continued separate PPI therapy is necessary given that Vimovo already contains esomeprazole. Double PPI use increases the risks associated with long-term acid suppression without proportional additional benefit for most patients.
What happens if I stop taking Vimovo MR tablets suddenly?
Stopping Vimovo suddenly does not carry the severe rebound risks associated with some medicines, but stopping the naproxen will result in a return of inflammatory pain and stiffness over the following days. Stopping the esomeprazole component may cause a temporary rebound increase in gastric acid secretion (acid hypersecretion rebound), which can produce heartburn symptoms. Discuss the plan for stopping or reducing Vimovo with your prescriber rather than discontinuing it abruptly.
Can Vimovo MR tablets be obtained on the NHS?
Vimovo is available on NHS prescription, though prescribing decisions are subject to local formulary guidelines and individual clinical assessment. Some NHS clinical commissioning groups or integrated care boards may prefer to prescribe naproxen and a separate PPI on cost grounds. Your GP can advise on local prescribing policy. Courier Pharmacy's online consultation service provides access to Vimovo via a private prescription for patients for whom NHS access is not straightforward.
Disclaimer: This article is for general information only and isn’t a substitute for personal medical advice, diagnosis, or treatment. Always check with a GP, pharmacist, or specialist before starting a new supplement if you have a medical condition or take regular medicines.
More than a prescription: our community
Managing a long-term inflammatory condition is a daily reality, and the system does not always make it easy to get the support you need between appointments. At Courier Pharmacy, we think accessible healthcare means being present even when no one is buying anything. Our free fortnightly drop-in clinics and talks at Insomnia, Derby run every other fortnight from 10 am to 12 pm.
Topics we cover regularly include managing chronic musculoskeletal and inflammatory conditions, NSAID safety, the role of gastroprotection, and how to have more productive conversations with your prescriber. If any of that sounds useful, you are very welcome to come along. No appointment, no charge, no pressure.
Learn more about our community talks and find the next session date at courierpharmacy.co.uk. Healthcare should be accessible, not just when you are buying. We mean that.
How this content was created
Written by the Courier Pharmacy editorial team and reviewed by a GPhC-registered pharmacist. Grounded in the latest NHS, NICE, BNF and EMC guidance, peer-reviewed studies, and the real questions patients bring to our drop-in clinics in Derby.
